NFKB1 and neoplasm: JAK inhibitors may block STAT3 signaling, but they can inadvertently activate NF-κB in macrophages, leading to the secretion of pro-survival factors such as IL-6 and CSF2, which activate tumor cell STAT3 and PI3K signaling through paracrine mechanisms, forming an escape loop from treatment.